Abstract
Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Adolescent Psychiatry
Title:Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis
Volume: 2 Issue: 2
Author(s): Kate V. Hardy and Rachel Loewy
Affiliation:
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Abstract: Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Export Options
About this article
Cite this article as:
Hardy Kate V. and Loewy Rachel, Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis , Adolescent Psychiatry 2012; 2 (2) . https://dx.doi.org/10.2174/2210676611202020172
DOI https://dx.doi.org/10.2174/2210676611202020172 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellulose Template Assembled Synthetic Peptides as Molecular Receptors
Current Protein & Peptide Science Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets Marine Algae As A Prospective Source For Antidiabetic Compounds – A Brief Review
Current Diabetes Reviews Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia Therapeutic Effects of Melatonin On Liver And Kidney Damages In Intensive Exercise Model of Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of the Binding Affinity of a Gonadotropin-Releasing Hormone Analogue (GnRH-a) Buserelin through <i>In silico</i> and <i>In vivo</i> Testing in <i>Clarias magur</i>
Current Proteomics Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening
Current Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Placental Transport of Folate and Thiamine: A Mini-Review
Current Women`s Health Reviews